ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks

Cell Cycle

Volumn 5, Issue 9, 2006, Pages 994-1000

  Nieborowska Skorska, Margaret ^a   Stoklosa, Tomasz ^b,c   Datta, Mandrita ^b   Czechowska, Agnieszka ^d   Rink, Lori ^a   Slupianek, Artur ^a   Koptyra, Mateusz ^a   Seferynska, Ilona ^e   Krszyna, Konrad ^c   Blasiak, Janusz ^d   Skorski, Tomasz ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY   (United States)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d UNIVERSITY OF LODZ   (Poland)

^e INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

Author keywords

ATR; BCR ABL; Checkpoint; Chk1; Drug resistance

Indexed keywords

ATR PROTEIN; BCR ABL PROTEIN; CAFFEINE; CHECKPOINT KINASE 1; CISPLATIN; DOUBLE STRANDED DNA; ENZYME INHIBITOR; HISTONE; HISTONE H2AX; MITOMYCIN C; SB 18078; UNCLASSIFIED DRUG;

ARTICLE; COMET ASSAY; CONTROLLED STUDY; DNA STRAND BREAKAGE; DRUG POTENTIATION; GENOTOXICITY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LEUKEMIA CELL; PHOSPHORYLATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PULSED FIELD GEL ELECTROPHORESIS;

EID: 33646414521     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.5.9.2722     Document Type: Article

References (77)

1. Tatosyan AG, Mizenina OA. Kinases of the Src family: Structure and functions. Biochemistry (Mosc) 2000; 65:49-58.
2. Porter AC, Vaillancourt RR. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 1998; 17:1343-52.
3. Sawyers CL. Signal transduction pathways involved in BCR-ABL transformation. Baillieres Clin Haematol 1997; 10:223-31.
4. Amarante-Mendes GP, Naekyung Kim C, Liu L, Huang Y, Perkins CL, Green DR, Bhalla K. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood 1998; 91:1700-5.
5. Masumoto N, Nakano S, Fujishima H, Kohno K, Niho Y. v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells. Int J Cancer 1999; 80:731-7.
6. Yu D, Hung MC. Role of erbB2 in breast cancer chemosensitivity. Bioessays 2000; 22:673-80.
7. 2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents. Blood 1995; 86:1148-58.
8. Dubrez L, Eymin B, Sordet O, Droin N, Turhan AG, Solary E. BCR-ABL delays apoptosis upstream of procaspase-3 activation. Blood 1998; 91:2415-22.
9. Maru Y, Bergmann E, Coin F, Egly JM, Shibuya M. TFIIH functions are altered by the P210BCR-ABL oncoprotein produced on the Philadelphia chromosome. Mutat Res 2001; 483:83-8.
10. Nishii K, Kabarowski JH, Gibbons DL, Griffiths SD, Titley I, Wiedemann LM, Greaves MF. ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. Oncogene 1996; 13:2225-34.
11. Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowicki MO, Pierce AJ, Fishel R, Skorski T. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 2001; 8:795-806.
12. Alimena G, De Cuia MR, Diverio D, Gastaldi R, Nanni M. The karyotype of blastic crisis. Cancer Genet Cytogenet 1987; 26:39-50.
13. Honda H, Ushijima T, Wakazono K, Oda H, Tanaka Y, Aizawa S, Ishikawa T, Yazaki Y, Hirai H. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: A transgenic study for blast crisis of human CML. Blood 2000; 95:1144-50.
14. Kelman Z, Prokocimer M, Peller S, Kahn Y, Rechavi G, Manor Y, Cohen A, Rotter V. Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia. Blood 1989; 74:2318-24.
15. Laneuville P, Sun G, Timm M, Vekemans M. Clonal evolution in a myeloid cell line transformed to interleukin-3 independent growth by retroviral transduction and expression of p210bcr/abl. Blood 1992; 80:1788-97.
16. Rowley JD, Testa JR. Chromosome abnormalities in malignant hematologic diseases. Adv Cancer Res 1982; 36:103-48.
17. Salloukh HF, Laneuville P. Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase. Leukemia 2000; 14:1401-4.
18. Sercan HO, Sercan ZY, Kizildag S, Undar B, Soydan S, Sakizli M. Consistent loss of heterozygosity at 14Q32 in lymphoid blast crisis of chronic myeloid leukemia. Leuk Lymphoma 2000; 39:385-90.
19. Gorre ME, Sawyers CL. Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol 2002; 9:303-7.
20. Weisberg E, Griffin JD. Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients. Drug Resist Updat 2001; 4:22-8.
21. Goga A, McLaughlin J, Afar DE, Saffran DC, Witte ON. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell 1995; 82:981-8.
22. Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG, Arlinghaus R, Pawson T. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 1994; 13:764-73.
23. Sawyers CL, McLaughlin J, Witte ON. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med 1995; 181:307-13.
24. Skorski T, Kanakaraj P, Ku DH, Nieborowska-Skorska M, Canaani E, Zon G, Perussia B, Calabretta B. Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: Implication for RAS-dependent Philadelphia chromosome positive cell growth. J Exp Med 1994; 179:1855-65.
25. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, Wasik MA, Tsichlis PN, Calabretta B. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 1997; 16:6151-61.
26. Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G, Gewirtz AM, Perussia B, Calabretta B. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995; 86:726-36.
27. de Groot RP, Raaijmakers JA, Lammers JW, Jove R, Koenderman L. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood 1999; 94:1108-12.
28. Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B, Skorski T. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med 1999; 189:1229-42.
29. Sonoyama J, Matsumura I, Ezoe S, Satoh Y, Zhang X, Kataoka Y, Takai E, Mizuki M, Machii T, Wakao H, Kanakura Y. Functional cooperation among Ras, STAT5 and PI3-K is required for full oncogenic activities of BCR/ABL in K562 cells. J Biol Chem 2002; 277:8076-82.
30. Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 2000; 95:2118-25.
31. Hoover RR, Gerlach MJ, Koh EY, Daley GQ. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells. Oncogene 2001; 20:5826-35.
32. von Willebrand M, Williams S, Saxena M, Gilman J, Tailor P, Jascur T, Amarante-Mendes GP, Green DR, Mustelin T. Modification of phosphatidylinositol 3-kinase SH2 domain binding properties by Abl- or Lck-mediated tyrosine phosphorylation at Tyr-688. J Biol Chem 1998; 273:3994-4000.
33. van der Kuip H, Goetz AW, Miething C, Duyster J, Aulitzky WE. Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis. Blood 2001; 98:1532-41.
34. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001; 15:2177-96.
35. Yang J, Yu Y, Hamrick HE, Duerksen-Hughes PJ. ATM, ATR and DNA-PK: Initiators of the cellular genotoxic stress responses. Carcinogenesis 2003; 24:1571-80.
36. Shiloh Y. ATM and related protein kinases: Safeguarding genome integrity. Nat Rev Cancer 2003; 3:155-68.
37. Nowicki MO, Falinski R, Koptyra M, Slupianek A, Stoklosa T, Gloc E, Nieborowska-Skorska M, Blasiak J, Skorski T. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 2004; 104:3746-53.
38. Slupianek A, Nowicki MO, Koptyra M, Skorski T. BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells. DNA Repair (Amst) 2006; 5:243-50.
39. Dasika GK, Lin SC, Zhao S, Sung P, Tomkinson A, Lee EY. DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis. Oncogene 1999; 18:7883-99.
40. Zhou BB, Elledge SJ. The DNA damage response: Putting checkpoints in perspective. Nature 2000; 408:433-9.
41. Shapiro GI, Harper JW. Anticancer drug targets: Cell cycle and checkpoint control. J Clin Invest 1999; 104:1645-53.
42. 2 delay potentiates cell death by apoptosis and/or the induction of giant cells in colorectal tumor cells with disrupted p53 function. Clin Cancer Res 1997; 3:1371-81.
43. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 1999; 401:616-20.
44. Elledge SJ. Cell cycle checkpoints: Preventing an identity crisis. Science 1996; 274:1664-72.
45. Zhou BB, Bartek J. Targeting the checkpoint kinases: Chemosensitization versus chemoprotection. Nat Rev Cancer 2004; 4:216-25.
46. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3:421-9.
47. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 2003; 13:49-58.
48. Fei P, El-Deiry WS. P53 and radiation responses. Oncogene 2003; 22:5774-83.
49. Stiewe T, Parssanedjad K, Esche H, Opalka B, Putzer BM. E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents. Cancer Res 2000; 60:3957-64.
50. 2M checkpoint in myeloid leukaemic cell lines results in loss of cell survival. Br J Haematol 2002; 119:956-64.
51. Stoklosa T, Slupianek A, Datta M, Nieborowska-Skorska M, Nowicki MO, Koptyra M, Skorski T. BCR/ABL recruits p53 tumor suppressor protein to induce drug resistance. Cell Cycle 2004; 3:1463-72.
52. Goldberg Z, Levav Y, Krichevsky S, Fibach E, Haupt Y. Treatment of chronic myeloid leukemia cells with imatinib (STI571) impairs p53 accumulation in response to DNA damage. Cell Cycle 2004; 3:1188-95.
53. 2/M phase, and protection from apoptosis. Mol Cell Biol 2002; 22:4189-201.
54. Wang H, Wang X, Zhou XY, Chen DJ, Li GC, Iliakis G, Wang Y. Ku affects the ataxia and Rad 3-related/CHK1-dependent S phase checkpoint response after camptothecin treatment. Cancer Res 2002; 62:2483-7.
55. Majsterek I, Gloc E, Blasiak J, Reiter RJ. A comparison of the action of amifostine and melatonin on DNA-damaging effects and apoptosis induced by idarubicin in normal and cancer cells. J Pineal Res 2005; 38:254-63.
56. Merk O, Reiser K, Speit G. Analysis of chromate-induced DNA-protein crosslinks with the comet assay. Mutat Res 2000; 471:71-80.
57. Rogakou EP, Boon C, Redon C, Bonner WM. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol 1999; 146:905-16.
58. Ward IM, Chen J. Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. J Biol Chem 2001; 276:47759-62.
59. Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 2001; 276:42462-7.
60. Stenerlow B, Karlsson KH, Cooper B, Rydberg B. Measurement of prompt DNA double-strand breaks in mammalian cells without including heat-labile sites: Results for cells deficient in nonhomologous end joining. Radiat Res 2003; 159:502-10.
61. Olive PL, Wlodek D, Banath JP. DNA double-strand breaks measured in individual cells subjected to gel electrophoresis. Cancer Res 1991; 51:4671-6.
62. Chowdhury D, Keogh MC, Ishii H, Peterson CL, Buratowski S, Lieberman J. gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair. Mol Cell 2005; 20:801-9.
63. 2/M checkpoint activation by etoposide through the Akt/GSK3 pathway to inhibit apoptosis. Oncogene 2005; 24:1973-81.
64. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2:561-6.
65. Sawyers CL. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Cancer Cell 2002; 1:13-5.
66. Tsao AS, Kantarijian H, Talpaz M. STI-571 in chronic myelogenous leukaemia. Br J Haematol 2002; 119:15-24.
67. Druker BJ. Imatinib and chronic myeloid leukemia: Validating the promise of molecularly targeted therapy. Eur J Cancer 2002; 38;S70-6.
68. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994-1004.
69. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349:1423-32.
70. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, Arber DA, Slovak ML, Forman SJ. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101:4701-7.
71. Wolff NC, Richardson JA, Egorin M, Ilaria Jr RL. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood 2003; 101:5010-3.
72. Hochhaus A, Hughes T. Clinical resistance to imatinib: Mechanisms and implications. Hematol Oncol Clin North Am 2004; 18:641-56.
73. Lahaye T, Riehm B, Berger U, Paschka P, Muller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: A 4.5-year follow-up. Cancer 2005; 103:1659-69.
74. Skorski T. BCR/ABL regulates response to DNA damage: The role in resistance to genotoxic treatment and in genomic instability. Oncogene 2002; 21:8591-604.
75. Dierov J, Dierova R, Carroll M. BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint. Cancer Cell 2004; 5:275-85.
76. Chen Y, Sanchez Y. Chk1 in the DNA damage response: Conserved roles from yeasts to mammals. DNA Repair (Amst) 2004; 3:1025-32.
77. Sorensen CS, Hansen LT, Dziegielewski J, Syljuasen RG, Lundin C, Bartek J, Helleday T. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 2005; 7:195-201.